

REMARKS**I. Status of the Claims**

Claims 1, 5, 6 and 8-10 are pending in the application. Claims 1, 6 and 10 have been amended to overcome the Examiner's rejections under 35 USC 112, second paragraph. The symbol "~" has been replaced by the word "to". This amendment to the claims is supported by Table 1 attached to the Declaration under 37 CFR 1.132 filed on June 14, 2007, which clearly indicates that the ratios recited in the claims are within the specified range. No new matter has been entered. The applicant confirms that the present invention as recited in the pending claims is directed to sustained release compositions for oral administration comprising the drug nifedipine, a mixture of sodium alginate and xanthan gum, representing the carrier for sustained release of nifedipine and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate, representing the gel hydration accelerator.

CONCLUSION

In view of the foregoing discussions, it is respectfully submitted that the present invention as defined in the pending claims 1, 5, 6 and 8-10 is in full compliance with all the statutory requirements, and therefore, it is earnestly requested that the Examiner's rejections be withdrawn and that the pending claims be allowed in their present form.

Respectfully submitted
For applicants,

By: 

Eugene Lieberstein
Registration No. 24,645


Dated: October 24, 2007

CUSTOMER NO. 01109
ANDERSON KILL & OLICK, P.C.
1251 Avenue of the Americas
New York, New York 10020-1182
(212) 278-1000

CERTIFICATE OF TRANSMISSION

I hereby certify that this Amendment and Request for Reconsideration is being deposited
Via EFS-Web addressed to: Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on October 24, 2007.

Audrey de Souza (Typed or printed name of person mailing paper or fee)

 (Signature of person mailing paper or fee)